

Date: 12.11.2021

To,

1. Department of Corporate Services BSE Limited P.J. Towers, Dalal Street, Mumbai-400 001	2. Metropolitan Stock Exchange of India Limited 205(A), 2 nd Floor, Piramal Agastya Corporate Park, Kamani Junction, LBS Road, Kurla (West), Mumbai-400 070
--	--

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 12.11.2021

Ref: Scrip Code: 539267, DRHABEEB

With reference to the subject cited above, this is to inform the Exchange that at the meeting of the Board of Directors of Dr Habeebullah Life Sciences Limited held on Friday, 12.11.2021 at 3.30 p.m. at the registered office of the Company at 6-3-354/13/B2, Flat. No. B2, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad-500034, Telangana, the following were considered and approved:

1. Unaudited financial results (standalone and consolidated) for the quarter and half-year ended 30.09.2021. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter and half-year ended 30.09.2021. **(Enclosed)**
3. Allotment of 64,00,000 equity shares at Rs. 10/- each by M/s. Krisani Bio Sciences Private Limited, Subsidiary Company of Dr Habeebullah Life Sciences Limited on a preferential basis and as a result the shareholding of the Company in Krisani Bio Sciences Private Limited has come down from 51.33% to 32.91% . Therefore, Krisani Bio Sciences Private Limited has ceased to be the subsidiary of the Company. For this purpose, the Company already obtained the consent the shareholders in the Annual General Meeting held on 15.09.2021 by way of passing the special resolution in terms of the provisions of the Companies Act, 2013 and as well as SEBI (LODR) Regulations, 2015.

The meeting concluded at 4.30 p.m. This is for the information and records of the Exchange, please.


Thanking you.

Yours sincerely,

For Dr Habeebullah Life Sciences Limited

K. Narendra Kumar

K. N.V. Narendra Kumar
Whole-time Director & CFO
DIN: 09223904



Encl: as above

Dr Habeebullah Life Sciences Ltd

Regd. Off & Corp Off : 6-3-354/13/B2,, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad-500082
.CIN No.: L85110TG1996PLC099198. Email: cs@drhlsl.com, info@drhlsl.com, pcproductsindia@gmail.com
Contact No.: 9490424639, Website : www.drhlsl.com


PART-I						(Amount in Lakhs.)	
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER II AND HALF YEAR ENDED 30TH SEPTEMBER, 2021							
S.No	Particulars	Quarter ended			Half Year ended		Year ended 31
		3 Months ended	Corresponding 3	Preceding 3	Half year ended	Half year ended	03-2021
		30-09-2021	months ended in	months ended	30-09-2021	30-09-2020	
		30-09-2020	30-06-2021				
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	-	-	-	-	1.30	1.30
II	Other Income	4.06	3.64	3.95	8.01	7.18	14.77
III	Total Revenue (I+II)	4.06	3.64	3.95	8.01	8.48	16.07
IV	Expenses	-	-	-	-	0.19	0.19
	Cost of Material Consumed	-	-	-	-	24.96	33.17
	Employee benefits expense	2.76	12.72	0.66	3.42	0.53	0.96
	Depreciation and Amortisation expense	0.13	0.27	0.13	0.26	39.61	58.72
	Other Expenses	3.06	21.13	7.57	10.63	65.29	93.04
	Total Expenses	5.95	34.12	8.36	14.31		
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(1.89)	(30.48)	(4.41)	(6.30)	(56.81)	(76.97)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(1.89)	(30.48)	(4.41)	(6.30)	(56.81)	(76.97)
VIII	Tax Expense:	-	-	-	-	-	-
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(1.89)	(30.48)	(4.41)	(6.30)	(56.81)	(76.97)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(1.89)	(30.48)	(4.41)	(6.30)	(56.81)	(76.97)
XIV	Other Comprehensive Income						
	A) (i) Items that will not be reclassified to profit or loss						
	(ii) Income Tax related to items that will not be reclassified to profit or loss						
	B) (i) Items that will be reclassified to profit or loss						
	(ii) Income Tax relating to items that will be reclassified to profit or loss		1.42	-	-	1.42	14.08
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(1.89)	(29.06)	(4.41)	(6.30)	(55.39)	(62.89)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)						
	1) Basic	(0.01)	(0.20)	(0.03)	(0.04)	(0.37)	(0.42)
	2) Diluted	(0.01)	(0.20)	(0.03)	(0.04)	(0.37)	(0.42)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)						
	1) Basic	-	-	-	-	-	-
	2) Diluted	-	-	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)						
	1) Basic	(0.01)	(0.20)	(0.03)	(0.04)	(0.37)	(0.42)
	2) Diluted	(0.01)	(0.20)	(0.03)	(0.04)	(0.37)	(0.42)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1480.87	1,480.87	1,480.87	1480.87	1480.87


Notes:

- The above unaudited standalone financial results for the quarter and half year ended 30 September 2021 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Friday 12th November 2021.
- The unaudited standalone financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of Companies Act, 2013 and other accounting principles generally accepted in India and in terms Regulation 33 of SEBI (LODR) Regulations, 2015.
- The format for the Standalone Unaudited quarterly and half year results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.2(i) has been availed.
- The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- The Previous quarters/ year's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

Place : Hyderabad
Date :12/11/2021

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju
Executive Chairman (DIN 00874650)




DR Habeebullah Life Sciences Limited		
Standalone Statement of Assets and Liabilities		
Particulars	(Amount in Lakhs.)	
	Half Year Ended 30/9/2021 (Unaudited)	Year Ended 31/3/2021 (Audited)
ASSETS		
1 Non Current Assets		
a Property, Plant and Equipment	1.52	1.79
b Capital Work In Progress	-	-
c Investment Property	-	-
d Goodwill	-	-
e Other Intangible Assets	-	-
f Intangible Assets under development	325.95	325.95
g Biological assets other than bearer plants	-	-
h Financial Assets:		
i Investments	487.06	487.06
ii Trade Receivables	-	-
iii Loans	-	-
iv Others	200.25	203.99
v Loans	-	-
vi Others	-	-
i Deferred Tax Assets (net)	-	-
j Other Non Current Assets	-	-
Total Non Current Assets	1,014.78	1,018.79
2 Current Assets		
a Inventories	12.92	12.92
b Financial Assets	-	-
i Investments	-	-
ii Trade Receivables	213.83	214.26
iii Cash and Cash Equivalents	1.32	0.41
iv Bank balances other than above	-	-
v Loans and Advances	134.00	134.00
vi Other financial assets	44.98	37.77
c Current Tax Assets (net)	-	-
d Other Current Assets	305.00	304.39
Total Current Assets	712.05	703.75
Total Assets	1,726.83	1,722.53
EQUITY AND LIABILITIES		
1 Equity		
a Equity Share Capital	1,480.87	1,480.87
b Other Equity	-	-
i Share Warrants	-	-
ii Reserves and Surplus	(307.13)	(300.83)
iii Non-Controlling Interests	-	-
Total - Equity	1,173.74	1,180.04
2 Liabilities		
Non Current Liabilities		
a Financial Liabilities	-	-
i Borrowings	-	-
ii Trade Payables	-	-
iii Other Financial Liabilities	-	-
b Provisions	4.56	4.56
c Deferred Tax Liabilities (net)	-	-
d Other Non Current Liabilities	-	-
Total Non Current Liabilities	4.56	4.56
Current Liabilities		
a Financial Liabilities		
i Borrowings	251.42	234.05
ii Trade Payables	21.50	28.72
iii Other Financial Liabilities	-	-
b Other Current Liabilities	275.60	275.15
c Provisions	-	-
d Current Tax Liabilities (net)	-	-
Total Current Liabilities	548.52	537.92
Total - Equity and Liabilities	1,726.83	1,722.53

For DR HABEEBULLAH LIFE SCIENCES LIMITED

Place: Hyderabad
Date: 12/11/2021


K. Krishnam Raju
Executive Chairman
(DIN 00874650)





DR HABEEBULLAH LIFE SCIENCES LIMITED
STANDALONE STATEMENT OF CASH FLOWS

(Amount in Lakhs.)

PARTICULARS	Half Year Ended September 30, 2021	Half Year Ended September 30, 2020
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(6.30)	55.39
<u>Adjustment for:</u>		
Depreciation and Amortisation	0.27	0.53
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	(6.04)	54.86
<u>Movements in Working Capital::</u>		
(Increase)/ Decrease in trade receivables	0.43	3.26
(Increase)/ Decrease in Short Term Loans and Advances	-	-
(Increase)/ Decrease in other Current Assets	(0.61)	(0.24)
(Increase)/ Decrease in other financial Assets	(7.21)	(6.65)
(Increase)/ Decrease in Inventories	-	0.19
Increase / (Decrease) in Trade Payables	(7.22)	4.43
Increase/ (Decrease) in Other current liabilities	0.45	38.00
Increase/ (Decrease) in Current Provisions	(0.00)	0.40
Change in Working Capital	(14.16)	39.40
<u>Changes in non current assets and liabilities</u>		
Decrease/(Increase) in loans & advances	3.74	-
(Decrease)/Increase in Long Term Borrowings	-	-
(Decrease)/Increase in Long Term Provisions	0	(0.01)
Changes in non current assets and liabilities	3.74	(0.01)
<u>Cash Generated From Operations</u>	(16.46)	(15.47)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(16.46)	(15.47)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) / Decrease in Fixed assets and Capital Work In progress	0	(18.23)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
-Balance of Unclaimed Dividend	-	-
Net cash used in Investing activities (B)	0	(18.23)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	-
Increase / (Decrease) in Borrowings	17.37	32.15
Interest paid	-	-
Net cash Flow from Financing Activities (C)	17.37	32.15
D. Effect of exchange differences on translation of foreign currency cash and cash equivalents	-	-
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	0.91	(1.55)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	0.41	2.35
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	1.32	0.80

For and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED


(K. Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650



Place: Hyderabad
Date: 12/11/2021




A.M. REDDY & D.R. REDDY

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Standalone unaudited Quarterly Financial results of Dr Habeebullah Life Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Dr Habeebullah Life Sciences Limited.

1. We have reviewed the accompanying statement of standalone unaudited financial results of Dr Habeebullah Life Sciences Limited ("the Company") for the quarter ended September 30, 2021 and year to date results for the period April 01, 2021 to September 30, 2021 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit Opinion.




4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Standalone Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A M Reddy & D R Reddy
Chartered Accountants
FRN:0090685

Devarapalli
Ramachandra
Reddy

Digitally signed by
Devarapalli Ramachandra
Reddy
Date: 2021.11.11 16:16:40
+05'30'

D.Rama Krishna Reddy
Partner
M.No.209211



Place : Hyderabad
Date: 12.11.2021

UDIN : 21209211AAAA09592.

PART-I CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER II AND HALF YEAR ENDED 30TH SEPTEMBER, 2021						(Amount in Lakhs.)	
S.No	Particulars	Quarter ended			Half Year ended		Year ended
		3 Months ended 30-09-2021	Corresponding 3 months ended in previous year 30-09-2020	Preceding 3 months ended 30-06-2021	Half year ended 30-09-2021	Half year ended 30-09-2020	31-03-2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	-	-	-	-	1.30	1.30
II	Other Income	4.06	3.64	3.95	8.01	7.18	14.77
III	Total Revenue (I+II)	4.06	3.64	3.95	8.01	8.48	16.07
IV	Expenses	-	-	-	-	0.19	0.19
	Cost of Material Consumed	-	-	-	3.42	26.16	34.97
	Employee benefits expense	2.76	13.32	0.66	0.27	0.66	1.21
	Depreciation and Amortisation expense	0.13	0.33	0.13	0.27	0.66	1.21
	Other Expenses	3.54	21.29	7.57	11.11	39.92	59.86
	Total Expenses	6.43	34.94	8.35	14.80	66.93	96.23
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(2.37)	(31.30)	(4.41)	(6.79)	(58.45)	(80.16)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(2.37)	(31.30)	(4.41)	(6.79)	(58.45)	(80.16)
VIII	Tax Expense:	-	-	-	-	-	-
	Current Tax	-	-	-	-	(1.04)	(2.49)
	Deferred Tax	-	(1.04)	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(2.37)	(30.26)	(4.41)	(6.79)	(57.41)	(77.67)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(2.37)	(30.26)	(4.41)	(6.79)	(57.41)	(77.67)
XIV	Other Comprehensive Income	-	-	-	-	-	-
	A) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax related to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B) (i) Items that will be reclassified to profit or loss	-	1.42	-	-	1.42	14.08
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(2.37)	(28.84)	(4.41)	(6.79)	(55.99)	(63.58)
XVI	Comprehensive Income attributable to Non Controlling Interest	(0.24)	(0.29)	-	0.00	(0.29)	(0.33)
XVII	Comprehensive Income attributable to Owners of the company	(2.13)	(28.55)	(4.41)	(6.79)	(55.70)	(63.24)
XVIII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)	-	-	-	-	-	-
	1) Basic	(0.02)	(0.19)	(0.03)	(0.05)	(0.38)	(0.43)
	2) Diluted	(0.02)	(0.19)	(0.03)	(0.05)	(0.38)	(0.43)
XIX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)	-	-	-	-	-	-
	1) Basic	-	-	-	-	-	-
	2) Diluted	-	-	-	-	-	-
XX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)	-	-	-	-	-	-
	1) Basic	(0.02)	(0.19)	(0.03)	(0.05)	(0.38)	(0.43)
	2) Diluted	(0.02)	(0.19)	(0.03)	(0.05)	(0.38)	(0.43)
XXI	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1480.87	1,480.87	1,480.87	1480.87	1480.87


Notes:

- The above unaudited consolidated financial results for the quarter and half year ended 30 September 2021 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Friday 12th November 2021.
- The unaudited consolidated financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of Companies Act, 2013 and other accounting principles generally accepted in India and in terms Regulation 33 of SEBI (LODR) Regulations, 2015.
- The format for the consolidated unaudited quarterly and half year ended results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.2(i) has been availed.
- The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- The Previous quarters' year's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

Place : Hyderabad
Date : 12/11/2021

For DR HABEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju
Executive Chairman (DIN 00874650)




DR Habeebullah Life Sciences Limited		
Consolidated Statement of Assets and Liabilities		
(Amount in Lakhs.)		
Particulars	Half Year Ended 3/9/2021	Year Ended 31/3/2021
ASSETS		
1 Non Current Assets		
a Property, Plant and Equipment	4.77	5.59
b Capital Work In Progress	-	-
c Investment Property	-	-
d Goodwill	-	-
e Other Intangible Assets	-	-
f Intangible Assets under development	1,940.33	1,939.78
g Biological assets other than bearer plants	-	-
h Financial Assets:		
i Investments	0.75	0.75
ii Trade Receivables	-	-
iii Loans	-	-
iv Others	200.25	203.99
v Loans	-	-
vi Others	-	-
i Deferred Tax Assets (net)	48.59	48.59
j Other Non Current Assets	-	-
Total Non Current Assets	2,194.69	2,198.70
2 Current Assets		
a Inventories	12.92	12.92
b Financial Assets	-	-
i Investments	-	-
ii Trade Receivables	213.83	214.26
iii Cash and Cash Equivalents	1.77	1.32
iv Bank balances other than above	-	-
v Loans	94.00	94.00
vi Other financial assets	44.98	37.77
c Current Tax Assets (net)	-	-
d Other Current Assets	306.66	306.04
Total Current Assets	674.16	666.31
Total Assets	2,868.84	2,865.01
EQUITY AND LIABILITIES		
1 Equity		
a Equity Share Capital	1,480.87	1,480.87
b Other Equity	-	-
i Share Warrants	-	-
ii Reserves and Surplus	(372.36)	(365.81)
iii Non-Controlling Interests	399.98	400.21
Total Equity	1,508.49	1,515.28
2 Liabilities		
Non Current Liabilities		
a Financial Liabilities	-	-
i Borrowings	-	-
ii Trade Payables	-	-
iii Other Financial Liabilities	-	-
b Provisions	4.56	4.56
c Deferred Tax Liabilities (net)	-	-
d Other Non Current Liabilities	-	-
Total Non Current Liabilities	4.56	4.56
Current Liabilities		
a Financial Liabilities		
i Borrowings	961.68	939.46
ii Trade Payables	21.51	28.72
iii Other Financial Liabilities	-	-
b Other Current Liabilities	372.60	376.98
c Provisions	-	-
d Current Tax Liabilities (net)	-	-
Total Current Liabilities	1,355.79	1,345.16
Total Equity and Liabilities	2,868.84	2,865.01

For DR HABEEBULLAH LIFE SCIENCES LIMITED

Place: Hyderabad
Date: 12/11/2021


 K. Krishnam Raju
 Executive Chairman
 (DIN 00874650)



DR HABEEBULLAH LIFE SCIENCES LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS


(Amount in Lakhs.)

PARTICULARS	Half Year ended September 30, 2021	Half Year ended September 30, 2020
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(6.79)	(57.03)
<u>Adjustment for:</u>		
Depreciation and Amortisation	0.27	0.66
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	(6.52)	(56.37)
<u>Movements in Working Capital::</u>		
(Increase)/ Decrease in trade receivables	0.43	3.26
(Increase) / Decrease in Short term Loans and Advances	-	-
(Increase)/Decrease in other financial assets Assets	(7.21)	(6.65)
(Increase)/Decrease in other Current Assets	(0.61)	(0.24)
(Increase) / Decrease in Inventories	-	0.19
Increase / (Decrease) in Trade Payables	47.94	4.43
Increase/(Decrease) in Other current liabilities	(59.53)	34.38
Increase/(Decrease) in Current Provisions	-	0.40
Change in Working Capital	(18.99)	35.78
<u>Changes in non current assets and liabilities</u>		
Decrease/(Increase) in loans & advances	3.74	-
(Decrease)/Increase in Long Term Provisions	-	(0.01)
Changes in non current assets and liabilities	3.74	(0.01)
<u>Cash Generated From Operations</u>	(21.77)	(20.61)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(21.77)	(20.61)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) / Decrease in Fixed assets and Capital Work In progress	-	18.23
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
-Balance of Unclaimed Dividend	-	-
Net cash used in Investing activities (B)	-	18.23
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	-
Increase / (Decrease) in Borrowings	22.22	37.31
Interest paid	-	-
Net cash Flow from Financing Activities (C)	22.22	37.31
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	0.45	(1.53)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	1.32	2.94
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	1.77	1.41

For and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED



(K. Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650



Place: Hyderabad
Date: 12/11/2021




A.M. REDDY & D.R. REDDY CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Consolidated unaudited Quarterly Financial results of Dr Habeebullah Life Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Dr Habeebullah Life Sciences Limited.

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Dr Habeebullah Life Sciences Limited ("the Holding Company"), its subsidiary, (the Holding company and its subsidiary together referred as the "group") for the quarter ended September 30, 2021 and year to date results for the period April 01, 2021 to September 30, 2021 ("the Statement") attached herewith, being submitted by the Holding company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the Holding company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit Opinion.



4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (listing obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement Includes the results of the Following Entities :

SN	Name of the Company	Relationship with the Holding Company
1	Krisani Bio Sciences Private Limited	Subsidiary

5. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Standalone Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The Consolidated unaudited financial results include the interim financial information of the subsidiary, (mentioned in paragraph 3 above) which have not been reviewed or audited by their auditors, whose interim financial information reflect total revenue (before consolidation adjustments) of Nil and Total Loss after Tax (before Consolidated adjustments) of Rs.2.13Lakhs for the quarter ended September 30,2021 respectively, as considered in the Statement. According to the information and Explanations given to us by the management, this interim financial information is not material to the Group

For A M Reddy & D R Reddy
Chartered Accountants
FRN:0090685

Devarapalli
Ramachandra
Reddy

Digitally signed by Devarapalli
Ramachandra Reddy
Date: 2021.11.11 16:05:40
+05'30'



D.Rama Krishna Reddy
Partner
M.No.209211

Place : Hyderabad
Date: 12.11.2021

UDIN : 21209211AAAACP1510 .